Videos

Panelists discuss how to effectively manage the safety profile of ruxolitinib when used in the treatment of chronic graft-versus-host disease, addressing potential adverse effects and monitoring strategies.

Panelists discuss how ruxolitinib has demonstrated efficacy as a second-line treatment strategy for chronic graft-versus-host disease, reviewing the available data on its effectiveness.

Andrea Necchi, MD, discusses how the findings from SunRISe-4 impact other data from the SunRISe group of clinical trials.

Stephen M. Ansell, MD, PhD, discusses the key takeaways from his session at 2024 Society of Hematologic Oncology Annual Meeting in the advanced stage Hodgkin lymphoma space.

Peter Schmid, MD, PhD, discusses his key takeaways from the phase 3 KEYNOTE-522 trial and the updated findings presented at the 2024 ESMO Congress.

Sarah Sammons, MD, provides an overview of the DESTINY-Breast03 trial.

Eric Jonasch, MD, discusses the mechanism of action of NKT-2152.

Meredith McKean, MD, discusses a longer-term follow-up study investigating fianlimab and cemiplimab immunotherapy in advanced melanoma.

Shirish M. Gadgeel, MD, discusses research that he is particularly excited to see presented at the 2024 European Society for Medical Oncology Congress.

Sergio A. Giralt, MD, discusses how to determine which patient is a candidate for transplant and the optimal time to perform a transplant in patients with myelodysplastic syndrome.

Kenneth Shain, MD, PhD, discusses why he recommends most patients with relapsed/refractory multiple myeloma be referred for evaluation to receive chimeric antigen receptor T-cell therapy.

Alessandra Ferrajoli, MD, discusses the session she was a part of at the 2024 Society of Hematologic Oncology Annual Meeting.

Renal cancer experts conclude their discussion by examining first-line immune checkpoint inhibitor-based combination therapies for metastatic renal cell carcinoma with sarcomatoid features, and offer their final insights on the current state and future directions of RCC treatment.

Panelists discuss how chronic graft-versus-host disease severity can be stratified to guide the tailoring of systemic treatments and supportive care strategies for optimal patient management.

Panelists discuss how a case study illustrates the multisystem manifestations of chronic graft-versus-host disease and demonstrate the application of NIH organ-specific scoring for comprehensive assessment.

Targeted Oncology co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for community oncologists to look out for at the upcoming ESMO Congress in Barcelona, with some additional tidbits to round out the main event.

Anil Parwani, MD, PhD, addresses potential biases or limitations in the artificial intelligence algorithm used at his institution.

Michael J. Mauro, MD, provides a summary of a presentation at the 2024 Society of Hematologic Oncology Annual Meeting on the recent advancements in CML treatment and applying clinical evidence to cases that are advanced.

Mikkael A. Sekeres MD, MS, discusses when he decides to start therapy for anemia in patients with low-risk myelodysplastic syndromes.

Craig A. Portell, MD, previews his session on sequencing therapies in relapsed/refractory mantle cell lymphoma being presented at the 2024 Society of Hematologic Oncology Annual Meeting.

Reid Merryman, MD, discusses the role of minimal residual disease in lymphoma and his presentation on the topic at the 2024 Society of Hematologic Oncology Annual Meeting.

Partow Kebriaei, MD, discusses transplant in acute lymphoblastic leukemia.

Sonali M. Smith, MD, discusses how T-cell–directed therapies work in the context of indolent B-cell lymphoma.

Experts on lower-risk MDS discuss when to switch to a topoisomerase inhibitor versus going to a hypomethylating agent.

Jamie Koprivnikar, MD, and Solly Chedid, MD, discuss ways to continue to advance the treatment landscape for lower-risk MDS, particularly in managing anemia and improving quality of life for patients.

Sergio A. Giralt, MD, discusses the current indications for considering stem cell transplants in patients with myelodysplastic syndrome.

Stefan Barta, MD, discusses the heterogeneity of T-cell lymphoma, highlighting that a one-size-fits-all approach is ineffective and emphasizing the need for tailored treatment approaches.

Sangeetha Venugopal, MD, MS, discusses how measurable residual disease is used during the course of treatment of AML.

Medical specialists analyze the case of a 58-year-old man presenting to the emergency room with hematuria and abdominal pain, while considering the most recent clinical data to inform their treatment approach for renal cell carcinoma.

Oncology experts examine their patient population demographics and discuss the percentage of clear cell renal cell carcinoma patients who progress to receive third-line and subsequent lines of therapy.